Galafold Amenability Table

Cookies

Amicus Therapeutics’ websites and mobile applications use cookies to maintain an optimal browsing and user experience. By continuing to view our website or use the mobile application, you consent to our use of cookies. Information about our use of cookies is set out below.

Cookies are small text files of letters and numbers that a website or mobile application may place or store on your computer or mobile device when you visit a site or page, or use a mobile application. Cookies are useful because they allow the website or mobile application to recognize your device the next time you visit or use it.  Cookies contain information that is transferred to your computer or mobile device.

How do Amicus Therapeutics websites and mobile applications use cookies?

The cookies we use perform different functions:

1. Strictly necessary cookies

We refer to some cookies as “strictly necessary” cookies because they are essential to enable our visitors to use certain features on our websites or mobile applications. For example, if you enter a username or password to access a secure section of our website or use a mobile application, a cookie may be placed on your computer or mobile device to keep you from having to enter these details more than once. These cookies do not record personal information that identifies you and are automatically deleted when you close your browser or delete the mobile application.

2. Performance cookies

These cookies are used to analyse how visitors use our website or mobile application, and to monitor our website’s or mobile application’s performance. For example, we may check which pages get the most visits and the average time spent on our website or mobile application. We use this information to improve how our websites and mobile applications work. These cookies do not record personal information that identifies you: the information that we receive from them is in the form of aggregated statistics.

These cookies are stored on your computer or device even when you close your browser but can be deleted as described in the paragraph ‘How can I control or delete cookies?’ below.

3. Functionality cookies

These cookies allow our website or mobile application to provide a more personal experience and remember any choices you may make. For example, if you visit our website using a mobile device but choose to access our main (non-mobile) site, a cookie may be set to prevent you from being re-directed to our mobile site. These cookies do not record personal information that identifies you. These cookies may be stored on your computer or mobile device even when you close your browser or the mobile application, but can be deleted as described in the paragraph ‘How can I control or delete cookies?’ below.

4. Targeting cookies

These cookies record your visit to our website or use of a mobile application, the pages you have visited and the links you have followed. We will use this information to make our website and mobile application, and the advertising displayed on it, more relevant to your interests. We may also share this information with third parties for this purpose.

You can find more information about the individual cookies we use and the purposes for which we use them in the table below:

Cookie Name Purpose More information
Load Balancer X-Mapping-(unique value) This cookie is used for server load balancing and to improve the performance of the website. It ties the visitor to the specific server which delivers content. None
Google Analytics and Google Tag Manager _ga_dc_gtm_ These cookies are used to collect information about how visitors use our site. We use the information to compile reports and to help us improve the site. The cookies collect information in an anonymous form, including the number of visitors to the site, where visitors have come to the site from and the pages they visited. Google Policies: https://www.google.com/intl/en/policies/

Please note that third parties (including, for example, providers of external services, like web traffic analysis services, or your mobile operator) may also use cookies, over which we have no control.

How can I control or delete cookies?

In relation to our website, most browsers are initially set up to automatically accept cookies that are placed on your computer or mobile device when you use websites. You can change the settings on your browser to block cookies or to alert you when cookies are being set on your computer or mobile device. You can also delete cookies stored on your computer or mobile device through your browser. Please refer to your browser instructions or Help screen to learn more about how to adjust or modify your browser settings.

Please note that parts of our websites [may not function correctly if you disable the cookies.

INDICATION

GALAFOLD® is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.

This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS
The most common adverse reactions reported with Galafold (>10 %) were headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.

DRUG INTERACTIONS
Avoid co-administration of Galafold with caffeine at least 2 hours before and 2 hours after taking Galafold.

USE IN SPECIFIC POPULATIONS
There is insufficient clinical data on Galafold use in pregnant women to inform a drug associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.

It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.

Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.

The safety and effectiveness of Galafold have not been established in pediatric patients.

To report Suspected Adverse Reactions, contact Amicus Therapeutics at 1-877-4AMICUS or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here for Full Prescribing Information.